OVARIAN NEOPLASMS
Clinical trials for OVARIAN NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new OVARIAN NEOPLASMS trials appear
Sign up with your email to follow new studies for OVARIAN NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cancer drug tested in early trial, but study stopped early
Disease control TerminatedThis early-stage trial tested an experimental drug called PF-08052666 in 19 people with advanced solid tumors like lung, ovarian, and pancreatic cancers that had not responded to standard treatments. The drug is designed to target and kill cancer cells. The study aimed to find a …
Matched conditions: OVARIAN NEOPLASMS
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New cancer drug trial halted early – what we know
Disease control TerminatedThis study tested a new drug, felmetatug vedotin, alone or with pembrolizumab, in people with advanced solid tumors like ovarian, breast, and lung cancer. The goal was to check safety and find the right dose. The trial was terminated early, so results are limited.
Matched conditions: OVARIAN NEOPLASMS
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Ovarian cancer drug trial halted early: what happened?
Disease control TerminatedThis study aimed to see if the drug niraparib works better than standard chemotherapy before surgery for people with a specific type of advanced ovarian cancer (stage III or IV with HRd). The trial was planned for 36 participants but was stopped early. Researchers wanted to measu…
Matched conditions: OVARIAN NEOPLASMS
Phase: PHASE2 • Sponsor: Tesaro, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New pill targets Hard-to-Treat cancers in early human test
Disease control TerminatedThis early-phase trial tested an experimental oral drug called NKT3447 in 23 adults with advanced or metastatic solid tumors that had stopped responding to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The study w…
Matched conditions: OVARIAN NEOPLASMS
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC